Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Clovis Oncology, Inc. CLVS
$0.08
-$0.02 (-24.11%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
0.00000000
-
week52high
3.25
-
week52low
0.04
-
Revenue
148757000
-
P/E TTM
0
-
Beta
0.22054500
-
EPS
-2.08400000
-
Last Dividend
0.00000000
-
Next Earnings Date
21 февр 2023 г. в 05:00
Описание компании
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Neutral | Buy | 06 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 05 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 21 сент 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 05 авг 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 05 мая 2021 г. |
| JP Morgan | Underweight | Neutral | 10 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rolfe Lindsey | D | 113691 | 2353 | 02 ноя 2022 г. |
| Rolfe Lindsey | D | 111419 | 1908 | 02 ноя 2022 г. |
| MUEHL DANIEL W | D | 104830 | 2066 | 02 ноя 2022 г. |
| MUEHL DANIEL W | D | 102271 | 2513 | 02 ноя 2022 г. |
| Harding Thomas C. | D | 3801 | 63 | 02 ноя 2022 г. |
| Harding Thomas C. | D | 19487 | 915 | 02 ноя 2022 г. |
| Harding Thomas C. | D | 18590 | 788 | 02 ноя 2022 г. |
| IVERS-READ GILLIAN C | D | 293612 | 2006 | 02 ноя 2022 г. |
| IVERS-READ GILLIAN C | D | 290993 | 1675 | 02 ноя 2022 г. |
| Gross Paul Edward | D | 98330 | 2135 | 02 ноя 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| SPDR S&P Biotech ETF | 8206440 | -422221 | 31 авг 2020 г. |
| Vanguard Total Stock Market Index Fund | 2415360 | 0 | 31 авг 2020 г. |
| iShares Russell 2000 ETF | 1540400 | 44080 | 31 авг 2020 г. |
| iShares Russell 2000 Growth ETF | 676564 | -6664 | 31 авг 2020 г. |
| Vanguard Extended Market Index Fund | 1265280 | -2646 | 31 июл 2020 г. |
| Vanguard Small-Cap Index Fund | 1041620 | -6160 | 31 июл 2020 г. |
| Vanguard Small-Cap Growth Index Fund | 639484 | -4059 | 31 июл 2020 г. |
| Fidelity Extended Market Index Fund | 429866 | 0 | 31 июл 2020 г. |
| Candriam Equities L Oncology Impact | 620428 | 248922 | 30 июн 2020 г. |
| Candriam Equities L Biotechnology | 551000 | 0 | 30 июн 2020 г. |
Новостная лента
Bet on 5 Top Stocks With Rising P/E
Zacks Investment Research
21 дек 2022 г. в 11:17
Forget undervalued stocks, play top-ranked stocks like Clovis Oncology (CLVS), NiSource (NI), DocuSign (DOCU), Root (ROOT) and Endava (DAVA).
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis
WSJ
12 дек 2022 г. в 14:05
Clovis Oncology, maker of ovarian cancer drug Rubraca, has filed for chapter 11 and proposed selling a separate therapy to a Novartis affiliate.
Clovis (CLVS) Files for Bankruptcy Amid Lack of Financial Aid
Zacks Investment Research
12 дек 2022 г. в 12:02
Recent regulatory developments force Clovis (CLVS) to file for bankruptcy. The company inks a stalking horse agreement with Novartis for one of its pipeline candidates.
CLVS Stock Alert: What to Know as Clovis Oncology Files for Bankruptcy
InvestorPlace
12 дек 2022 г. в 10:26
Clovis Oncology (NASDAQ: CLVS ) stock is on the move Monday as investors react to the pharmaceutical company filing for bankruptcy protection. The first thing that investors need to know about is Clovis Oncology's plan for this bankruptcy.
Clovis Oncology stock slides 10% premarket after company files for bankruptcy
Market Watch
12 дек 2022 г. в 06:37
Clovis Oncology Inc. stock CLVS, -9.94% fell 10% in premarket trade Monday, after the biotech filed for Chapter 11 bankruptcy and said it would sell assets. The company has a commitment for up to $75 million in debtor-in-possession financing to provide the liquidity needed to restructure in bankruptcy and pay its vendors and customers.